Skip to Content
Merck
All Photos(1)

Documents

I8907

Sigma-Aldrich

Interferon β from rat

≥95%, recombinant, expressed in CHO cells, lyophilized powder, suitable for cell culture

Synonym(s):

IFN-β

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352202
NACRES:
NA.32

biological source

rat

Quality Level

recombinant

expressed in CHO cells

Assay

≥95%

form

lyophilized powder

mol wt

~20 kDa

packaging

pkg of 1 vial

concentration

≥100000 units/mL

technique(s)

cell culture | mammalian: suitable

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

Biochem/physiol Actions

Interferon β belongs to the type 1 interferon family pf proteins. It is also needed for the inhibition of tumor cell growth via cell death, S-phase increase and mediating differentiation. It is also important for bone homeostasis.
Cytokine with anti-viral, anti-proliferative, immunoregulatory, and proinflammatory activities.

Physical form

Lyophilized from phosphate buffered saline (PBS) containing 125 mM trehalose.

Analysis Note

The biological activity is determined in the cytopathic effect inhibition assay using rat epithelial-like (RATEC) cells with vesicular stomatitis virus (VSV). The cytopathic effect of 50% is produced with approximately 1 unit/ml interferon. Since there is no international rat interferon β standard, units are determined with respect to the NIH international standard reference for mouse interferon α/β.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R B Pepinsky et al.
The Journal of pharmacology and experimental therapeutics, 297(3), 1059-1066 (2001-05-18)
Interferon therapies suffer from a relatively short half-life of the products in circulation. To address this issue we investigated the effects of polyethylene glycol modification (PEGylation) on the pharmacokinetic properties of human interferon (IFN)-beta-1a. PEGylation with a linear 20-kDa PEG
C Ren et al.
Gene therapy, 15(21), 1446-1453 (2008-07-04)
Cell-based therapy for cancer is a promising new field. Among cell types that can be used for this purpose, mesenchymal stem cells (MSCs) appear to hold great advantage for reasons including easier propagation in culture, possible genetic modification to express
J Adriaansen et al.
Human gene therapy, 17(10), 985-996 (2006-09-21)
Interferon (IFN)-beta has significant immunomodulatory properties and has received much interest as a potentially therapeutic agent for rheumatoid arthritis (RA). Systemic IFN-beta treatment of patients with RA was not effective, probably because of pharmacokinetic issues. Therefore, we studied the effect
Junqiang Ye et al.
PloS one, 6(6), e20681-e20681 (2011-06-17)
The production of type I interferons (IFNs) in response to viral infections is critical for antiviral immunity. However, IFN production is transient, and continued expression can lead to inflammatory or autoimmune diseases. Thus, understanding the mechanisms underlying the negative regulation
Interferon standards and general abbreviations.
S Pestka
Methods in enzymology, 119, 14-23 (1986-01-01)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service